Merrimack Announces U.S. FDA Approval of ONIVYDE™ (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Go back to Merrimack Announces U.S. FDA Approval of ONIVYDE™ (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer| (NYSE: BXLT) | Delayed: 46.02 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.02 | 52 Week High | $46.52 | |||
| Open | $16.43 | 52 Week Low | $29.83 | |||
| Day High | $46.02 | P/E | N/A | |||
| Day Low | $46.02 | EPS | $0.00 | |||
| Volume | 72,381 | |||||
| MERRIMACK PHARM (NASDAQ: MACK) | Delayed: 15.13 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.13 | 52 Week High | $9.63 | |||
| Open | $0.00 | 52 Week Low | $4.39 | |||
| Day High | $15.13 | P/E | N/A | |||
| Day Low | $15.13 | EPS | $-1.24 | |||
| Volume | 3,325,453 | |||||
